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Purpose: To define intramyocardial triglyceride (TG), creatine (Cr), and choline (Cho)
in healthy volunteers, and determine the feasibilities, scan durations and agreements
between cardiac proton magnetic resonance spectroscopy ([1H]-MRS) performed with
fewer signal averages versus a reference standard with 128 signal averages.
Materials and methods: Thirty-one participants underwent [1H]-MRS using 16, 32, 64,
and 128 signal averages. Intramyocardial TG, Cr, or Cho contents relative to water were
calculated and expressed as a percentage.
Results: Mean intramyocardial TG, Cr, and Cho were 1.301.13, 0.190.18, and
0.240.28%, respectively. The feasibilities for quantifying intramyocardial TG, Cr, and
Cho using fewer signal averages ranged from 93.5 to 100, 90.3 to 93.5, and 90.3
to 96.8%, respectively. Scan durations for 16, 32, 64, and 128 signal averages were
1.10.5, 2.60.9, 5.92.0, and 13.24.5min, respectively (p<0.001). Agreements
with the reference standard 128 signal average was higher for quantification of intramy-
ocardial TG compared to Cr and Cho.
Conclusion: Quantification of intramyocardial TG with [1H]-MRS with only 64 signal
averages was highly feasible, showed excellent agreement with 128 signal averages,
and had significantly shorter scan duration. By contrast, quantifying Cr and Cho using
fewer signal averages had lower feasibilities and agreements compared to 128 signal
averages.
Keywords: magnetic resonance, spectroscopy, myocardial, metabolites, left ventricle
Introduction
The study of intracellular metabolites in response to pathophysiological stimuli can provide insights
into the mechanisms underlying disease states. Currently, one of the methods used for in vivo
quantification of these metabolites includes proton magnetic resonance spectroscopy ([1H]-MRS)
(Figure 1) using point resolved spectroscopy sequence (PRESS) with cardiac and respiratory gating
(1). Previous [1H]-MRS studies have demonstrated changes in intramyocardial concentrations of
triglyceride (TG), creatine (Cr), and choline (Cho) in various cardiac pathologies such as diabetic
heart disease and heart failure (2–7). Intramyocardial TG is increased in diabetic and obese patients
in a process synonymous with “fatty liver” disease (2–4). Intramyocardial Cr is a marker of the
total cardiac energetic system and is required in the production of adenosine triphosphate (ATP).
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FIGURE 1 | Example of cardiac proton magnetic resonance
spectroscopy with voxel of interest placed at interventricular septum
(left panels). Unsuppressed water content peaks at 4.7 ppm (top right panel).
Intramyocardial triglyceride was quantified by summing the amplitudes of lipid
resonances at 0.9 and 1.3 ppm, while choline and creatine peaks at 3.2 and
3.0 ppm, respectively (bottom right panel).
Creatine depletion has been shown to correlate well with the
extent of myocardial ischemia post infarction and the degree of
myocardial dysfunction in cardiac failure (8–10). Choline has a
wide role in human metabolism, including neurotransmitter syn-
thesis (acetylcholine), cell-membrane signaling (phospholipids),
lipid transport (lipoproteins), and methyl-group metabolism
(homocysteine reduction). Although previous studies have eval-
uated intramyocardial TG in healthy and diabetic patients (2–4),
no studies to date have quantified intramyocardial Cr and Cho in
a cohort of healthy volunteers.
Presently, quantification of intramyocardial metabolites by
[1H]-MRS is frequently performed using 32 up to 128 signal
averages (Figure 1) (11–13). Acquiring more signal averages will
improve spectral quality by improving signal-to-noise ratio. How-
ever, acquiring 128 signal averages is extremely time consuming
due to need for cardiac and respiratory motion gating to reduce
cardiac and respiratory motion artifacts (11). Often, patients can-
not tolerate extended periods of examinations within the mag-
netic resonance imaging (MRI) machine. No studies to date have
evaluated the agreements between [1H]-MRS of different signal
averages.
Therefore, the aims of the present study were to quantify
intramyocardial TG, Cr, andCho in a cohort of healthy volunteers,
and to determine the feasibilities, scan durations, and agreements
between [1H]-MRS performed with fewer signal averages versus
the reference standard with 128 signal averages.
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Materials and Methods
Patient Population and Study Protocol
A total of 31 healthy volunteers without known medical illnesses
were prospectively recruited. These subjects were specifically
recruited in this research study to determine intramyocardial
metabolite levels in healthy people. Exclusion criteria included
age <18 years, pregnancy, rhythm other than sinus rhythm, pre-
viously known significant coronary artery disease, left ventricu-
lar (LV) systolic dysfunction or previous myocardial infarction,
moderate or severe valvular stenosis or regurgitation, diabetes
mellitus, hypercholesterolemia, active smoker, inability to provide
informed consent, and inability to undergo a cardiac MRI.
All participants underwent a cardiac MRI examination after an
overnight fast. LV volumes, ejection fraction (EF), and mass were
quantified. Intramyocardial metabolites (including TG, Cr, and
Cho) were quantified by [1H]-MRS. The feasibilities, accuracies,
and scan durations of individual separate water-suppressed [1H]-
MRS signals with only 16, 32, and 64 averages were comparedwith
the reference standard spectrum with 128 signal averages.
The study was approved by the institutional ethics committee
and all subjects provided informed consent.
Cardiac Magnetic Resonance Imaging
All participants underwent a cardiac MRI examination using
a 1.5-T Siemens Magnetom Avanto (Erlangen, Germany) sys-
tem. During the examination, the entire heart was imaged
in the short-axis orientation with ECG-gated breath-hold bal-
anced steady state free-precession imaging. Imaging parameters
included the following: echo time (TE)= 1.0ms, repetition time
(TR)= 57.9ms, flip-angle= 54°, slice thickness= 8mm with a
gap of 2mm, field of view= 340mm 340mm, reconstructed
matrix size= 156 192.
Left ventricular end-diastolic volume index (EDVI) and end-
systolic volume index (ESVI) were measured and corrected for
body-surface area (BSA) (14). LVEF was then calculated and
expressed as a percentage. LV mass (excluding papillary muscles)
was also measured and indexed to BSA. All images were digitally
stored on hard disks and analyzed offline using dedicated quan-
titative software (MASS V2010-EXP, Leiden University Medical
Center, Leiden, The Netherlands).
Cardiac Proton MR Spectroscopy
Cardiac [1H]-MRS was performed as previously described (2).
Briefly, [1H]-MRS spectra were obtained by PRESS with a 6mL
voxel (1 cm 2 cm 3 cm) placed in the interventricular sep-
tum using the four-chamber and short-axis views at end-diastole.
Spectroscopic data acquisitions were double-triggered with ECG
triggering and respiratory navigator echoes to minimize motion
artifacts. End-diastolic spectra were acquired with the following
parameters: TE= 25ms, TR= 2000ms, 1024 data points, band-
width 1000Hz. Automatic shimming was performed before the
spectroscopy data acquisition using the gradient-recalled echo
shim technique whereby a field map was generated from a single-
slab double-echo 3D gradient-recalled echo acquisition with two
in-phase TEs with respect to fat and water, which were then used
to calculate the shim currents to improve B0 homogeneity.
Water-suppressed spectra were acquired to quantify
intramyocardial metabolites (including TG, Cr, and Cho).
To determine the feasibilities, scan durations, and accuracies of
water-suppressed [1H]-MRS with fewer signal averages, individ-
ual spectra with 16, 32, and 64 signal averages were acquired and
compared with the reference standard spectrum with 128 signal
averages. Non-water-suppressed spectra were acquired with 16
signal averages and used as an internal standard (see next section).
In between spectra acquisitions, the volume of interest was kept
fixed within the interventricular septum and not adjusted.
Spectral Quantification
[1H]-MRS data were fitted by use of Java-based MR user inter-
face software (jMRUI version 2.2, Leuven, Belgium) AMARES
algorithm as previously described (2). Water-suppressed spec-
tra with 16, 32, 64, and 128 averages were used to quantify
intramyocardial TG, Cr, and Cho content. Resonance frequency
estimates for intramyocardial TG, Cr, and Cho were described
by assuming Lorentzian line shapes. Intramyocardial TG was
quantified by summing the amplitudes of lipid resonances at
0.9 and 1.3 ppm, while Cho and Cr peaks at 3.2 and 3.0 ppm,
respectively (Figure 1). Quantification of intramyocardial TG, Cr,
and Cho was deemed not feasible if no clear peaks were visible
at the expected respective resonance frequencies, and when the
Lorentzian curve fitting by jMRUI could not be performed. To
determine the adequacy and accuracy of the fitted signal ampli-
tude, the relative Cramer–Rao standard deviation (CRSD) was
calculated as previously published (15). The CRSD was deter-
mined using the AMARES algorithm, and then divided by the
lipid signal amplitude. This generates a relative CRSD, which is
inversely proportional to signal-to-noise ratio.
Unsuppressed spectra were acquired with 16 averages to deter-
mine water content, which peaks at 4.7 ppm. This water peak
signal was used for internal standardization, and its quantification
was feasible in all subjects.
Intramyocardial TG, Cr, and Cho contents relative to water
were calculated and expressed as a percentage based on:
(signal amplitude of TG, Cr, or Cho)/(signal amplitude of
water) 100 (2).
Statistical Analysis
Continuous variables were presented as mean 1 SD unless oth-
erwise stated, and categorical variables were presented as frequen-
cies and percentages. Comparisons between the two groups of
subjects with feasible versus any non-feasible [1H]-MRS analyses
were performed using Mann–Whitney U-test and Chi-square
test for continuous and categorical variables, respectively. Pear-
son correlation was employed to examine the linear association
between two continuous variables. Comparison of feasible ver-
sus any non-feasible [1H]-MRS analyses with increasing number
of signal averages (i.e., ordinal data) was performed using Chi-
square test with linear-by-linear association. Agreements between
[1H]-MRS of fewer signals averages (i.e., with 16, 32, and 64
signal averages) and the reference standard spectrum with 128
signal averages were performed using intraclass correlations and
Bland and Altman plots (16). Differences between the four groups
of [1H]-MRS of different signal averages were compared using
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repeated measures analysis of variance (ANOVA). A two-tailed p
value of <0.05 was considered significant. All statistical analyses
were performed using IBM SPSS Statistics for Windows, version
21.0 (Armonk, NY, USA).
Results
A total of 31 participants (21 male) were recruited. The mean age
and BMI were 35 11 years and 24.4 4.4 kg/m2, respectively.
The mean height was 175.2 9.1 cm and weight was 75 14 kg.
The mean heart rate, LVEDVI, LVESVI, LVEF, and LV mass
were 66 12 beats/min, 92.6 15.9mL/m2, 41.8 7.6mL/m2,
54.5 3.0%, and 86.5 22.6 g, respectively.
Intramyocardial Metabolites in Healthy
Volunteers
As shown in Table 1, using 128 signal averages as the reference
standard, it was possible to quantify intramyocardial TG and
Cho in all 100% of patients, and intramyocardial Cr in 96.8% of
patients. The mean intramyocardial TG, Cr, and Cho concentra-
tions were 1.30 1.13, 0.19 0.18, and 0.24 0.28%, respectively.
There were no significant differences in intramyocardial TG, Cr,
and Cho betweenmale and female gender (all p> 0.05). Similarly,
there were no correlations between intramyocardial TG, Cr, and
Cho with age, LV mass, volumes, and EF (all p> 0.05).
Scan Durations and Feasibilities of Spectroscopy
with Fewer Signals
Table 2 outlines the scan durations and feasibilities for quantifying
intramyocardial TG, Cr, and Cho contents relative to water. The
mean scan duration for the reference standard [1H]-MRS with
128 signal averages was 13.2 4.5min (range 10.1–29.7min).
As expected, [1H]-MRS with fewer signal averages had signifi-
cantly shorter scan durations compared to the reference standard
(p< 0.001 by repeated measures ANOVA; Figure 2).
However, [1H]-MRS with fewer signal averages had lower
feasibilities for quantification of intramyocardial metabolites
(Table 2). Accordingly, the total feasibilities for quantifying all 3
intramyocardial metabolites using [1H]-MRS of 16, 32, 64, and
128 signal averages were 77.4, 87.1, 90.3, and 96.8%, respectively
(p= 0.020 by Chi square with linear-by-linear association). As a
TABLE 1 | Intramyocardial metabolite contents and intraclass correlations
for spectra with fewer signal averages versus reference standard with 128
signal averages.
Number of
signals
Triglyceride
(ICC)
Creatine
(ICC)
Choline
(ICC)
16 averages 1.341.22%
(0.941)
0.270.30%
(0.585)
0.270.37%
(0.872)
32 averages 1.331.18%
(0.973)
0.210.21%
(0.650)
0.240.25%
(0.915)
64 averages 1.431.27%
(0.977)
0.220.20%
(0.812)
0.240.27%
(0.924)
128 averages
(reference standard)
1.301.13% 0.190.18% 0.240.28%
ICC, intraclass correlation.
result, it was possible to quantify all 3 intramyocardial metabolites
from all 4 spectra of different signal averages in 23 subjects.
Figure 3 shows the mean relative CRSD (an inverse measure of
the signal-to-noise ratio of the accuracy of the fitted signal ampli-
tude) for the intramyocardial metabolites. As expected, increas-
ing signal averages were associated with an improvement in the
signal-to-noise ratio.
Compared to the 23 subjects where it was possible to quantify
all 3 intramyocardial metabolites from all 4 spectra, participants
with any non-feasible [1H]-MRS analyses had a trend toward
lower intramyocardial TG (0.92 0.90 versus 1.43 1.19%,
p= 0.30), Cr (0.17 0.16 versus 0.19 0.19%, p= 0.68), and Cho
contents (0.10 0.06 versus 0.29 0.31%, p= 0.26). There were
no significant differences in age, gender, heart rate, LV mass,
volumes, or EF (all p> 0.05).
Agreements with Reference Standard
Spectroscopy
Table 1 outlines the intramyocardial TG, Cr, and Cho contents
using [1H]-MRS of different number of signal averages, and
their intraclass correlations with the reference standard [1H]-
MRS with 128 signal averages. As shown, [1H]-MRS with more
signal averages had better agreements with the 128 signal average
TABLE 2 | Scan durations and feasibilities of cardiac proton magnetic
resonance spectroscopy for quantifying intramyocardial metabolites.
Number of
signals
Scan
duration
(min)
Triglyceride
(% feasibility)
Creatine
(% feasibility)
Choline
(% feasibility)
16 averages 1.10.5 93.5 90.3 90.3
32 averages 2.60.9 100 90.3 96.8
64 averages 5.92.0 100 93.5 96.8
128 averages
(reference
standard)
13.24.5 100 96.8 100
FIGURE 2 | Scan durations for cardiac proton magnetic resonance
spectroscopy with 16, 32, 64, and 128 signal averages.
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FIGURE 3 |Mean relative Cramer–Rao standard deviation for the intramyocardial triglyceride, creatine, and choline. Increasing signal averages resulted
in progressively lower relative Cramer–Rao standard deviation and therefore a higher signal-to-noise ratio.
FIGURE 4 | Bland and Altman plots showing narrower limits of agreement and no significant bias for quantification of intramyocardial triglyceride,
creatine, and choline with progressively more signal averages acquired during proton magnetic resonance spectroscopy.
reference standard, and Bland and Altman plots showed pro-
gressively narrower limits of agreement with no significant bias
(Figure 4). As a group, there were no significant differences in
intramyocardial TG, Cr, and Cho contents derived from [1H]-
MRSof differing signal averages (all p> 0.05 by repeatedmeasures
ANOVA).
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Discussion
The present study evaluated intramyocardial TG, Cr, and Cho
in a large cohort of healthy volunteers, and demonstrated that
it was feasible to quantify intramyocardial metabolites using
fewer [1H]-MRS signal averages and shorter scan duration.
However, the accuracies and signal-to-noise ratios were sub-
optimal when intramyocardial metabolite concentrations were
low, especially for Cr and Cho compared to TG. Therefore,
intramyocardial TG can be accurately quantified with signif-
icantly lower signal averages once a discernible peak is visi-
ble on [1H]-MRS, but accurate quantification of Cr and Cho
should be performed using 128 signal averages as the reference
standard.
Physiological Roles of Intramyocardial
Metabolites
Quantification of intramyocardial metabolites can provide
insights into various disease states. A typical myocardial [1H]-
MRS spectrum will display signals from water, TG, Cr, and Cho
as shown in Figure 1. Under normal physiological conditions,
the heart utilizes both free fatty acids and glucose as the primary
source of energy. However, increased nutritional fatty acid intake
and increased lipolysis in diabetes or obesity lead to increased
free fatty acid delivery to the heart (17–19). The excessive fatty
acids are stored as TGs within the myocyte cytoplasm, and
part of it is redirected into non-oxidative pathways giving rise
to toxic fatty acid intermediates (5, 20) These toxic fatty acid
intermediates disrupt normal cellular signaling and alter myocyte
function and structure, eventually causing cellular apoptosis
and replacement fibrosis. Previous study has demonstrated that
intramyocardial TG content increases with normal aging, and
is inversely correlated with age-related decline in LV diastolic
function (3). Similarly, intramyocardial TG accumulation occurs
in pathological states such as diabetes, and is dependently
associated with myocardial dysfunction (21–23). These findings
were replicated in experimental animal studies showing a direct
toxic effect of fatty acid intermediates on themyocardium (24, 25).
Therefore, it is likely that intracellular TG is inert, but is reflective
of the increased intracellular concentrations of toxic fatty acid
intermediates.
In contrast, Cr is a marker of cardiac energetic system and is
required in the production of ATP in the Krebs cycle (5). [1H]-
MRS can quantify the total pool of phosphorylated and unphos-
phorylated creatine in themyocardium, and ismore sensitive than
phosphorus MRS (26). Both Bottomley et al. and Nakae et al.
previously demonstrated that the total pool of Cr is reduced in
patients with ischemic heart disease and heart failure, respectively
(9, 26). Furthermore, total Cr pool was significantly lower in
patients with more severe heart failure (9).
Finally, Cho has a wide ranging role in human metabolism and
is required for neurotransmitter synthesis (acetylcholine), cell-
membrane signaling (phospholipids), lipid transport (lipopro-
teins), and methyl-group metabolism (homocysteine reduction)
(6). Dietary deficiency of Cho may be associated with myocardial
fibrosis and steatosis, restrictive pericarditis, myocardial necrosis,
pericardial effusions, and atherosclerosis (6, 7). However, there
is limited literature on quantification of intramyocardial Cho
concentration.
Cardiac Proton Magnetic Resonance
Spectroscopy
There are multiple fundamental technical challenges, which have
significantly limited the use of [1H]-MRS despite considerable
clinical potential (27). Currently, quantification of intramyocar-
dial metabolites by [1H]-MRS is performed using 128 signal
averages as a clinical reference standard (11). However, acquiring
128 signal averages is time consuming due to need for cardiac
and respiratory motion gating to reduce motion artifacts. In the
present study, the scan durations for acquiring [1H]-MRS with
128 signal averages ranged from approximately 10 to 30min, and
were not inclusive of the time required for scan planning and
other clinical routine sequences such as cine. Therefore, total MRI
examination duration is usually longer than 1 h when performing
[1H]-MRS. To the best of our knowledge, the present study is, first,
to determine the feasibilities, scan durations, and accuracies of
performing [1H]-MRS with fewer signal averages. For intramy-
ocardial TG that has higher relative concentrations compared to
Cr and Cho, [1H]-MRS can be performed with significantly fewer
signal averages and still maintain high technical feasibility without
loss of quantification accuracy. It could be expected that clinical
studies of patients with diseasedmyocardiumwould be evenmore
feasible using fewer averages, as intramyocardial TG levels are
increased. However, acquiring fewer signal averages decreases the
signal-to-noise ratio as reflected in the higher CRSD. Therefore,
intramyocardial metabolites such as Cr and Cho, which have
significantly lower relative concentrations, could not be easily
and accurately quantified using fewer signal averages. This would
be compounded in clinical scenarios where patients with heart
failure or myocardial infarction will have metabolite depletion
(10). Furthermore, the clear spectral separation of the Cr and
Cho peaks at 3.0 and 3.2 ppm, respectively, is reduced when
fewer [1H]-MRS signals were acquired. It is also less feasible
to accurately quantify all three intramyocardial metabolites in
patients with inherently low concentrations without acquiring 128
averages.
Conclusion
In summary, quantification of intramyocardial TG with [1H]-
MRS can be accurately performed using only 64 averages with
significant time savings. Therefore, it is feasible to use 64 averages
to quantify intramyocardial TG in future clinical studies. How-
ever, quantification of Cr and Cho should be performed using the
more sensitive clinical reference standard of 128 signal averages
due to their low intramyocardial concentrations.
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